320 pages | 50 Color Illus. | 18 B/W Illus.
Multiple myeloma is the second most prevalent hematological malignancy, with over 55,000 new cases diagnosed each year. This exciting new text, edited by lauded authorities on the topic, stands as the only available reference to assemble, review, and synthesizes the latest studies on translational therapies and clearly explains the impact of molecular pathogenesis, biology, and prognostic factors on the diagnosis, prognosis, and individualization of treatment and the development of novel therapeutic options for patients with myeloma.
Moving from the bench to the bedside to the forefront of therapeutic development, this source:
Molecular Biology, Cytogentics. Molecular Mechanisms of Growth. Animals Models in MM. Role of bone marrow microenvironment in pathogenesis of multiple myeloma. Myeloma Bone Disease. Niches within the Mutiple Myeloma bone marrow microenviriment. Novel Therapeutic Targets in MM. Monoclonal Gammopathy of Undetermined Significance. Prognostic Factors and Classification in Mutiple Myeloma. Novel Agents for Previously Untreated Mutiple Myeloma. Novel Options of Therapy- - Relapsed. High Dose Therapy in MM. Promising New Agents in phase I and II clinical trials in Multiple Myeloma. Immunotherapy in MM. Novel Therapeutic Options in Primary Systemic Amyloidosis. Novel Options of therapy in Waldenstrom Macroglobulinemia.